UpdatedMon, May 3, 2021 at 4:35 pm ET
Reply
Leapfrog Group gave D safety grades to Phoenixville and Pottstown hospitals in its spring report, while Chester County Hospital and Paoli Hospital received A s. (Shutterstock)
PHOENIXVILLE, PA Hospital safety grades from Leapfrog were low for several Tower Health hospitals in Chester County, including Phoenixville Hospital, Brandywine Hospital, and Pottstown Hospital.
The three facilities were awarded grades of D by the Leapfrog Group, an organization the performs regular assessments of hospitals. Numerous Pennsylvania hospitals received top safety marks while others didn t quite measure up in The Leapfrog Group s annual spring safety grades.
The nonprofit health care watchdog group grades hospitals twice a year, assigning letter grades from A to F based on each hospital s ability to protect patients from preventable errors, accidents, injuries, and infections.
Reply
(Shutterstock)
LIMERICK-ROYERSFORD-SPRING CITY, PA The U.S. has reached what health officials have called a complicated stage of the COVID-19 pandemic, with cases and hospitalizations increasing in some parts of the country despite the quickening pace of vaccination.
Nationally, the seven-day average of new cases, which had fallen steadily from its peak of nearly 250,000 in January, is rising again, the Centers for Disease Control and Prevention said. Over the week ending April 14, new cases averaged 69,577 8.1 percent higher than during the previous week, when the seven-day average stood at 64,340. More than 31.2 million cases of COVID-19 have been reported since the pandemic began.
Arch Oncology Appoints Laurence Blumberg, M.D. President and CEO
April 07, 2021 08:00 ET | Source: Arch Oncology Arch Oncology Brisbane, California, UNITED STATES
BRISBANE, Calif. and ST. LOUIS, April 07, 2021 (GLOBE NEWSWIRE) Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody therapies, today announced the appointment of Laurence Blumberg, M.D. as President and Chief Executive Officer and Board Member. Dr. Blumberg has over thirty years of biotechnology industry experience leading companies as an executive, founder, analyst, and board member.
“On behalf of the Board, I welcome Laur to Arch Oncology as he brings extensive industry experience to lead the Company’s plans for AO-176, a novel anti-CD47 therapy for patients with cancer,” said John McKearn, Ph.D., Managing Director, RiverVest Venture Partners and Chairman of the Board of Arch Oncology.
Arch Oncology Appoints Laurence Blumberg, M.D. President and CEO
News Provided By
Share This Article
/EIN News/ BRISBANE, Calif. and ST. LOUIS, April 07, 2021 (GLOBE NEWSWIRE) Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody therapies, today announced the appointment of Laurence Blumberg, M.D. as President and Chief Executive Officer and Board Member. Dr. Blumberg has over thirty years of biotechnology industry experience leading companies as an executive, founder, analyst, and board member.
“On behalf of the Board, I welcome Laur to Arch Oncology as he brings extensive industry experience to lead the Company’s plans for AO-176, a novel anti-CD47 therapy for patients with cancer,” said John McKearn, Ph.D., Managing Director, RiverVest Venture Partners and Chairman of the Board of Arch Oncology. “AO-176 has a differentiated and potentially best-in-class profile among anti-CD47 biologic therap
Reply
(Shutterstock)
POTTSTOWN, PA Although health officials warn that it s too soon for the nation to let down its guard in the fight against the coronavirus, many indicators point to a gradual easing of the pandemic, including a sharp drop in the number of new hospitalizations.
The Centers for Disease Control and Prevention reports that admissions of confirmed COVID-19 patients has fallen by two-thirds since their peak in early January, with the seven-day average dropping from 16,540 on Jan. 9 to 5,490 on March 2. The latter figure was nearly 15 percent lower than the week before.
Still, the pressure on hospital capacity has not disappeared, federal figures show.